Phesgo
Payments companies reported to CMS as associated with Phesgo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Phesgo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Phesgo
These are the largest totals companies reported as associated with Phesgo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $18,633.87 |
| Maria Theodoulou | Albany, NY | Medical Oncology | $15,550.78 |
| Andrew Seidman | New York, NY | Medical Oncology | $14,780.85 |
| Joyce O'Shaughnessy | Dallas, TX | Medical Oncology | $6,159.26 |
| Sujith Kalmadi | Chandler, AZ | Hematology & Oncology | $5,751.31 |
| Yuan Yuan | Pasadena, CA | Medical Oncology | $5,709.44 |
| Vijayakrishna Gadi | Seattle, WA | Medical Oncology | $4,069.44 |
| Joseph Sparano | Bronx, NY | Medical Oncology | $4,069.44 |
| Abirami Sivapiragasam | Syracuse, NY | Hematology & Oncology | $3,957.04 |
| Jason Mouabbi | Houston, TX | Medical Oncology | $3,882.63 |
Prescribed Phesgo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.